Results 31 to 40 of about 22,236,668 (323)
Treatment-related Adverse events (AEs).
Treatment-related Adverse events (AEs).
Hiroaki Shiba (12530426) +10 more
core +2 more sources
ObjectiveTo study the incidence and distribution of adverse events in immune checkpoint inhibitors (ICI) for digestive system cancers and to provide a reference for the safe, rational, and effective use of immune detection site inhibitors.MethodsWe ...
Liqiu Kou +8 more
doaj +1 more source
The association between adverse events and outcome under checkpoint inhibitors: Where is the deal?
Recent reports have put into evidence the possibility of a link between immune-related adverse events (IRAEs) and treatment outcome, patients drawing a benefit from treatment being also exposed to the risk to develop toxicity.A still unanswered question ...
Gerard Milano +2 more
doaj +1 more source
Treatment-related adverse events as surrogate to response rate to immune checkpoint blockade. [PDF]
Abstract Background: Immune checkpoint blockade (ICB) brings hope to many late-stage cancer patients yet its marker for response remains elusive. Methods: We developed a hypothesis that treatment-related adverse ...
Shen Y, Chen Y, Wang D, Zhu Z.
europepmc +4 more sources
Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma. [PDF]
Abstract Tremendous progress has been made in the clinical landscape of advanced-stage BRAF V600–mutant melanoma treatment over the past 5 years. Targeted therapies that inhibit specific steps of the mitogen-activated protein kinase pathway have been shown to provide significant overall treatment benefit in patients with this difficult ...
A. Daud, K. Tsai
semanticscholar +5 more sources
Effects of immune‐related adverse events (irAEs) and their treatment on antitumor immune responses
Immune checkpoint inhibitors (ICIs) are potentially life‐saving cancer therapies that can trigger immune‐related adverse events (irAEs). irAEs can impact any organ and range in their presentation from mild side effects to life‐threatening complications ...
Steven M. Blum, S. Rouhani, R. Sullivan
semanticscholar +1 more source
Background To determine whether antibiotic treatment is a risk factor for immune-related adverse events (irAEs) across different patients with cancer receiving anti-PD-1/PD-L1 therapies.
Ying Jing +15 more
semanticscholar +1 more source
Treatment-related adverse events (TRAEs) (n = 12).
Treatment-related adverse events (TRAEs) (n = 12).
Naoya Maekawa (575840) +19 more
core +1 more source
In recent years, immunotherapy-based regimens have been included into the treatment's algorithm of several cancer types. Programmed death-1 (PD-1) and cytotoxic T lymphocyte antigen-4 (CTLA-4) interact with their ligands found on the surface of antigen ...
P. Iranzo +13 more
semanticscholar +1 more source
Capecitabine-induced hypertriglyceridemia: a rare but clinically relevant treatment-related adverse event [PDF]
Capecitabine-induced hypertriglyceridemia (CIHT) represents an increasingly significant treatment-related adverse event from capecitabine given its potential for both acute complications (acute pancreatitis) and chronic metabolic complications (cardiovascular disease). The incidence of CIHT is relatively rare and the majority of cases thus far reported
An, Uche +6 more
openaire +2 more sources

